PRESS RELEASE

Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery

Preclinical data support the potential of PoxSTG-EEV to overcome key barriers to systemic (IV) delivery and enhance tumor dissemination of oncolytic viruses

Strasbourg, France, November 3, 2026, 5:45 p.m. CET – **Transgene (Euronext Paris: TNG)**, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that **new preclinical data on PoxSTG-EEV, its novel enveloped chimeric oncolytic virus, have been selected for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.**
SITC will take place November 4 - 8, 2026, in Phoenix, Arizona (USA).

These data highlight the potential of **PoxSTG-EEV, a next-generation chimeric oncolytic virus with a novel Extracellular Enveloped Virion (EEV) formulation developed by Transgene** to enhance intratumoral dissemination and increase resistance to immune-mediated neutralization, supporting its potential for systemic (IV) administration.

"Oncolytic viruses have shown considerable promise in cancer treatment, however their full therapeutic potential could be further enhanced by improvements related to systemic delivery and intratumoral spread," said **Katell Bidet-Huang, Chief Scientific Officer *ad interim* at Transgene**. *"These preclinical findings demonstrate the potential of PoxSTG-EEV to address some of these barriers and highlight the continued innovation from Transgene's viral vector expertise."*

"*PoxSTG-EEV combines the PoxSTG chimeric viral vector backbone, with an EEV-enriched formulation designed to generate and preserve the EEV form of the virus and serves as the backbone for Transgene's proprietary EEVOLV™ platform, supporting the development of a new generation of poxvirus-based-clinical candidates*" added **Johann Foloppe, PhD, Senior scientist and Project leader at Transgene.**

Preclinical studies showed that compared with conventional oncolytic vaccinia viruses, PoxSTG-EEV enhanced cytotoxic activity across multiple tumor cell lines and intratumoral dissemination, while maintaining infectivity in the presence of active complement and neutralizing antibodies. In mouse models, intravenous administration significantly reduced tumor growth and prolonged survival.

Poster Details

Title: "PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery"

- **Abstract number**: 1050
- **Date**: November 7, 2026
- **Authors**: Johann Foloppe, Juliette Kempf, Michèle Klein, Julie Hortelano, Baptiste Moreau, Laurine Gault, Isabelle Farine, Philippe Erbs

The poster will be available on the websites of SITC and Transgene on November 7, 2026, at 9:00 a.m. ET.

***

Contacts

Transgene:
Media:
Caroline Tosch-Pourchot
Corporate and Scientific Communications Manager
+33 (0)3 68 33 27 38
communication@transgene.fr

Investors & Analysts:
Lucie Larguier
Chief Financial Officer (CFO)
+33 (0)3 88 27 91 00/21
investorrelations@transgene.fr

MEDiSTRAVA
Frazer Hall/Sylvie Berrebi
+ 44 (0)203 928 6900
transgene@medistrava.com

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing virus-based targeted immunotherapies and vaccines. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. Transgene's *myvac*® platform is designed to develop individualized neoantigen therapeutic vaccines (INTVs), with potential across multiple solid tumor types.

TG4050, the first INTV based on the *myvac*® platform is the Company's lead asset, with demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070, the second *myvac*®-based INTV introduces Transgene's proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities and is in Phase 1 clinical development in combination with nivolumab in the adjuvant treatment of non-small cell lung cancer (NSCLC). The Company's other viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. Transgene also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.

With Transgene's *myvac*® platform, therapeutic vaccination enters the field of precision medicine with an immunotherapy tailored to each individual patient. The *myvac*® approach enables the generation of virus-based immunotherapies encoding patient-specific neoantigens. Transgene has further expanded the platform's capabilities with its own proprietary AI-driven neoantigen selection and scalable cell-line manufacturing.

Leveraging its MVA and cell-line manufacturing expertise, Transgene is developing TG-MVA™, a next-generation prophylactic vaccine candidate against mpox and smallpox designed to address key manufacturing and supply challenges.

Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: www.transgene.com

Follow us on social media: LinkedIn: @Transgene — X: @TransgeneSA — Bluesky: @Transgene

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.